Health-related Quality of Life in Long-Term Breast Cancer Survivors : Differences by Adjuvant Chemotherapy Dose in Cancer and Leukemia Group B Study 8541

摘要: BACKGROUND: The Survivor's Health and Reaction (SHARE) study examined health-related quality of life (HRQL) in breast cancer patients who had participated Cancer Leukemia Group B Trial 8541 from 1985 to 1991. METHODS: In total, 245 survivors (78% eligible patients) were 9.4 16.5 years postdiagnosis (mean, 12.5 postdiagnosis) completed HRQL surveys relating 5 domains. Analyses domains according 3 different chemotherapy dose levels that administered the original treatment trial: low-dose cyclophosphamide, doxorubicin, fluorouracil (CAF) at 300 mg/m2, 30 300×2 respectively, over 4 cycles; standard-dose CAF 400 40 400×2 6 high-dose 600 60 mg/m2 600×2 cycles. RESULTS: In univariate analyses, a statistically significant difference was observed on Medical Outcomes Study 36-item short form Physical Role Functioning subscale by group, with lower mean scores standard arm 65.05) compared 74.66) 84.94; P.0001). However, multivariate analysis revealed no longer significant, whereas following factors associated decreased physical role functioning: age ≥60 (odds ratio [OR], 3.55; P = .006), increased comorbidity interference total score (OR, 1.64; .005), vitality 1.05; .0002), menopausal symptoms 1.04 .02). CONCLUSIONS: At 9.4-16.5 after their diagnosis, differences functioning among received explained clinical demographic variables, such as age, fatigue, symptoms, comorbidities. Prospective studies are needed further assess these explaining long-term survivors. 2009. © 2009 American Society.